Increased Advisory Cmte. Preparation Ahead May Challenge FDA, Sponsors
Executive Summary
The potential upturn in the number of advisory committees convened by FDA could translate into a significant increase in the behind-the-scenes meeting preparation workload for both industry and the agency
You may also be interested in...
Advisory Panel For Bristol's Yervoy Is Called Off, Which May Bode Well
After extending the review, FDA says it no longer needs ODAC's advice on the second-line melanoma treatment, which looks like a good sign for approval.
Advisory Panel For Bristol's Yervoy Is Called Off, Which May Bode Well
After extending the review, FDA says it no longer needs ODAC's advice on the second-line melanoma treatment, which looks like a good sign for approval.
FDA Panel Advice To Limit Aquavan Administration Would Also Limit Market
If FDA takes an advisory panel's advice to limit approval of MGI Pharma's Aquavan (fospropofol) to administration only by trained anesthesiologists, the market for the sedative - which would then compete directly with its active moiety, propofol - would be substantially limited